Multidrug-resistant tuberculosis in europe, 2010-2011

Emerging Infectious Diseases

Volumn 21, Issue 3, 2015, Pages 409-416

  Günther, Gunar ^a,b   Van Leth, Frank ^c   Alexandru, Sofa ^d   Altet, Neus ^e,f   Avsar, Korkut ^g   Bang, Didi ^h,i   Barbuta, Raisa ^j   Bothamley, Graham ^k   Ciobanu, Ana ^d   Crudu, Valeriu ^d,l   Danilovits, Manfred ^m   Dedicoat, Martin ^n,o   Duarte, Raquel ^p,q   Gualano, Gina ^r   Kunst, Heinke ^o,s   De Lange, Wiel ^t   Leimane, Vaira ^u   Magis Escurra, Cecile ^v   McLaughlin, Anne Marie ^w   Muylle, Inge ^x   Polcová, Veronika ^y   Pontali, Emanuele ^z   Popa, Christina ^aa   Rumetshofer, Rudolf ^ab   Skrahina, Alena ^ac   Solodovnikova, Varvara ^ac   Spinu, Victor ^aa   Tiberi, Simon ^ad,ae   Viiklepp, Piret ^af   Lange, Christoph ^a,b,ag   Rowhani, Marcel ^ah   Avchinko, Vera ^ah   Katovich, Dzimitry ^ah   Klimuk, Dzimitri ^ah   Lobik, Valentina ^ah   Rohaya, Zoya ^ah   Shirochyn, Alexander ^ah   Kotrbova, Jana ^ah   Vasakova, Martina ^ah   Andersen, Aase Bengard ^ah   Smitsman, Nelleke ^ah   Mütterlein, Ralf ^ah   De Lorenzo, Saverio ^ah   Rusmane, Liga ^ah   Donica, Ana ^ah   Cernenco, Ilie ^ah   Dubceac, Vera ^ah   Cuppen, Femke ^ah   De Guchtenaire, Inge ^ah   Meesters, Robert ^ah   Te Pas, Mark ^ah   Prins, Bram ^ah   Atunes, Ana ^ah   Gainaru, Dan ^ah   Ibraim, Elmira ^ah   Tigau, Mirela ^ah   Cayla, Juan ^ah   Fina, Laia ^ah   De Souza Galvao, Maria Luiza ^ah   Maldonado, José ^ah   more..

^a UNIVERSITY OF NAMIBIA   (Namibia)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Microbiology and Morphology Laboratory   (Moldova)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Jordi Gol University   (Spain)

^g ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^h STATENS SERUM INSTITUT   (Denmark)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j Balti Municipal Hospital   (Moldova)

^k HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^l Phthisiopneumology Institute   (Moldova)

^m TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁿ UNIVERSITY OF WARWICK   (United Kingdom)

^o UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^p Vila Nova de Gaia Espinho Medical Center   (Portugal)

^q UNIVERSITY OF PORTO   (Portugal)

^r NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^s QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^t UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^u RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^w ST JAMES S HOSPITAL   (Ireland)

^x Microbiology Department   (Belgium)

^y FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^z GALLIERA HOSPITAL   (Italy)

^aa Marius Nasta Institute   (Romania)

^ab OTTO WAGNER HOSPITAL   (Austria)

^ac National Research and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

^ad Reference Hospital for MDR and HIV TB   (Italy)

^ae BARTS HEALTH NHS TRUST   (United Kingdom)

^af NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^ag KAROLINSKA INSTITUTE   (Sweden)

^ah NONE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE TRANSMISSION; ELECTRONIC MEDICAL RECORD; EUROPE; FEMALE; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFORMATION PROCESSING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; QUALITY CONTROL; RISK FACTOR; SMOKING; SPUTUM CULTURE; SPUTUM SMEAR; TRAINING; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECTS; GENETICS; HEALTH SURVEY; HISTORY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84923127789     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2103.141343     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis report 2013. Geneva: The Organization; 2013.
2. World Health Organization. WHO global task force outlines measures to combat XDR-TB worldwide. 2006 [cited 2014 May 10]. http://www.who.int/mediacentre/news/notes/2006/np29/en/
3. European Centre for Disease Prevention and Control/WHO Regional Offce for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm: The Centre; 2014.
4. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis. 1978;53:70-5.
5. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300
6. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fuoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156-68. http://dx.doi.org/10.1183/09031936.00134712
7. van der Werf MJ, Kodmön C, Hollo V, Sandgren A, Zucs P. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill. 2014;19:pii:20733.
8. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Knowledge of tuberculosis-treatment prescription of health workers: a systematic review. Eur Respir J. 2012;39:1248-55. http://dx.doi.org/10.1183/09031936.00125611
9. Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo DM, et al. TBNET: collaborative research on tuberculosis in Europe. Eur J Microbiol Immunol (Bp). 2012;2:264-74.http://dx.doi.org/10.1556/EuJMI.2.2012.4.4
10. European Centre for Disease Prevention and Control/WHO Regional Offce for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: The Centre; 2013.
11. World Health Organization. Defnitions and reporting framework for tuberculosis—2013 revision [cited 2014 May 20].http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
12. Lange C, Abubakr I, Alfenaar JW, Bothamley G, Caminero JA, Calvarho AC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44:23-63. http://dx.doi.org/10.1183/09031936.00188313
13. Kreuter F, Valliant R. A survey on survey statistics: what is done and can be done in Stata. Stata J. 2007;7:1-21.
14. Lemeshow S, Letenneur L, Dartigues JF, Lafont S, Orgogozo JM, Commenges D. Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study. Am J Epidemiol. 1998;148:298-306. http://dx.doi.org/10.1093/oxfordjournals.aje.a009639
15. van Leth F, Kalisvaart NA, Erkens CG, Borgdoff MW. Projection of the number of patients with tuberculosis in the Netherlands in 2030. Eur J Public Health. 2009;19:424-7. http://dx.doi.org/10.1093/eurpub/ckp042
16. World Health Organization. Office for Europe: roadmap to prevent and combat drug-resistant tuberculosis, 2011 [cited 2014 Sep 18]. http://www.euro.who.int/en/publications/abstracts/roadmap-to-prevent-and-combat-drug-resistant-tuberculosis
17. Uys PW, Warren R, van Helden PD, Murray M, Victor TC. Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol. 2009;47:1484-90. http://dx.doi.org/10.1128/JCM.02289-08
18. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J. 2012;39:1511-9. http://dx.doi.org/10.1183/09031936.00125711
19. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91:36-45. http://dx.doi.org/10.2471/BLT.12.104588
20. Royce S, Falzon D, van Weezenbeek C, Dara M, Hyder K, Hopewell P, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis. 2013;17:511-3. http://dx.doi.org/10.5588/ijtld.12.0286
21. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6:1-33 [cited 2014 Nov 13]. http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf
22. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406-17. http://dx.doi.org/10.1016/S0140-6736(12)60734-X
23. Hoffner S. Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control. Lancet. 2012;380:1367-9. http://dx.doi.org/10.1016/S0140-6736(12)61069-1
24. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049-63. http://dx.doi.org/10.1093/cid/ciu572
25. Van Deun A, Kya Jai Maug A, Halim MA, Kumar Das P, Ranjan Sarker M, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-92. http://dx.doi.org/10.1164/rccm.201001-0077OC
26. Singh KP, Brown M, Murphy ME, Gillespie SH. Moxifoxacin for tuberculosis. Lancet Infect Dis. 2012;12:176, author reply 177-8. http://dx.doi.org/10.1016/S1473-3099(11)70350-4
27. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:6-14. http://dx.doi.org/10.1086/653115
28. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med. 2009;150:766-75. http://dx.doi.org/10.7326/0003-4819-150-11-200906020-00004
29. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:2161-70. http://dx.doi.org/10.1056/NEJMoa1108789
30. Hillemann D, Hoffner S, Cirillo D, Drobniewski F, Richter E, Rusch-Gerdes S. First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries. PLoS ONE. 2013;8:e76765. http://dx.doi.org/10.1371/journal.pone.0076765